AKESO(09926) 智通财经网·2025-04-28 02:34Group 1 - Jianyin International raised the target price for Kangfang Biopharma (09926) by 33.3%, from HKD 90 to HKD 120, reflecting improved earnings forecasts and high potential for the company's lung cancer drugs in China and overseas [1] - Kangfang Biopharma's fundamentals are strong, with revenue forecasts for 2025, 2026, and 2027 increased to RMB 3.3 billion, RMB 5.3 billion, and RMB 9.6 billion respectively, and adjusted profit forecasts for 2025, 2026, and 2027 raised to RMB 121 million, RMB 1.2 billion, and RMB 3.9 billion respectively [1] - The approval of Ebdarokimab for moderate to severe plaque psoriasis in China is a significant milestone for Kangfang Biopharma [1] Group 2 - On April 23, Kangfang Biopharma announced that its drug AK112 met the target efficacy in a Phase 3 clinical trial for advanced squamous non-small cell lung cancer, showing superior efficacy compared to Tislelizumab [2] - The independent data monitoring committee confirmed that AK112's efficacy is significantly better than that of Tislelizumab, aligning with previously published Phase 3 clinical data [2] - AK112's performance indicates it outperforms Merck's well-known PD-1 biologic competitor, Keytruda [2]